title: Upcoming drugs for the treatment of preeclampsia in pregnant women.
abstract: Preeclampsia is a pregnancy-specific multisystem disorder, complicating 2 - 8% of pregnancies, and represents a leading cause of maternal and perinatal morbidity and mortality. Recent investigations have elucidated the understanding of its underlying pathogenic mechanisms. However, despite these advances, therapeutic approaches are still severely limited. Ongoing lines of research indicate some potential novel therapeutic options, targeting the etiopathogenic pathways and, thus, offering hope for effective pharmacologic interventions to be available in the near future. In this editorial, we will give an updated overview of Preeclampsia pathogenesis and promising emerging therapeutic options.
authors: Department of Obstetrics and Gynecology, University of Milano-Bicocca, via Pergolesi 33, Monza, MB, Italy.
authors: Sara
authors: S
authors: Ornaghi
authors: Michael J
authors: MJ
authors: Paidas
mesh_terms: D000818:Animals; D015195:Drug Design; D005260:Female; D006801:Humans; D008428:Maternal Mortality; D011225:Pre-Eclampsia / Q000188:drug therapy* / Q000503:physiopathology; D011247:Pregnancy
keywords: ETA receptor antagonists; Preeclampsia; RLX030; anti-digoxin antibody; endothelial dysfunction; lipid apheresis; mesenchymal stem cells; nitric oxide modulators; recombinant human antithrombin; statins